Clinical Implication of Sequential Circulating Tumor DNA Assessments for the Treatment of Diffuse Large B-Cell Lymphoma
Simple Summary
Abstract
1. Introduction
2. Patients and Methods
2.1. Patients and Sample Collection
2.2. Next-Generation Sequencing Library
2.3. LymphGen Classifier
2.4. Statistical Analyses
3. Results
3.1. Patient Characteristics and Responses to Treatment
3.2. Detection of ctDNA at Diagnosis
3.3. Associations of Interim ctDNA with Treatment Response and Survival
3.4. Combined Interim Response Assessment Incorporating ctDNA and PET/CT
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Susanibar-Adaniya, S.; Barta, S.K. 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. Am. J. Hematol. 2021, 96, 617–629. [Google Scholar] [CrossRef] [PubMed]
- Diaz, L.A., Jr.; Bardelli, A. Liquid biopsies: Genotyping circulating tumor DNA. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2014, 32, 579–586. [Google Scholar] [CrossRef]
- Lauer, E.M.; Mutter, J.; Scherer, F. Circulating tumor DNA in B-cell lymphoma: Technical advances, clinical applications, and perspectives for translational research. Leukemia 2022, 36, 2151–2164. [Google Scholar] [CrossRef]
- Roschewski, M.; Rossi, D.; Kurtz, D.M.; Alizadeh, A.A.; Wilson, W.H. Circulating Tumor DNA in Lymphoma: Principles and Future Directions. Blood Cancer Discov. 2022, 3, 5–15. [Google Scholar] [CrossRef]
- Kurtz, D.M.; Scherer, F.; Jin, M.C.; Soo, J.; Craig, A.F.M.; Esfahani, M.S.; Chabon, J.J.; Stehr, H.; Liu, C.L.; Tibshirani, R.; et al. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2018, 36, 2845–2853. [Google Scholar] [CrossRef]
- Kurtz, D.M.; Soo, J.; Co Ting Keh, L.; Alig, S.; Chabon, J.J.; Sworder, B.J.; Schultz, A.; Jin, M.C.; Scherer, F.; Garofalo, A.; et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat. Biotechnol. 2021, 39, 1537–1547. [Google Scholar] [CrossRef]
- Roschewski, M.; Dunleavy, K.; Pittaluga, S.; Moorhead, M.; Pepin, F.; Kong, K.; Shovlin, M.; Jaffe, E.S.; Staudt, L.M.; Lai, C.; et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: A correlative biomarker study. Lancet. Oncol. 2015, 16, 541–549. [Google Scholar] [CrossRef]
- Swerdlow, S.H.; Campo, E.; Pileri, S.A.; Harris, N.L.; Stein, H.; Siebert, R.; Advani, R.; Ghielmini, M.; Salles, G.A.; Zelenetz, A.D.; et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016, 127, 2375–2390. [Google Scholar] [CrossRef]
- Cheson, B.D.; Fisher, R.I.; Barrington, S.F.; Cavalli, F.; Schwartz, L.H.; Zucca, E.; Lister, T.A. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2014, 32, 3059–3068. [Google Scholar] [CrossRef]
- Genovese, G.; Kähler, A.K.; Handsaker, R.E.; Lindberg, J.; Rose, S.A.; Bakhoum, S.F.; Chambert, K.; Mick, E.; Neale, B.M.; Fromer, M.; et al. Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence. N. Engl. J. Med. 2014, 371, 2477–2487. [Google Scholar] [CrossRef]
- Jaiswal, S.; Fontanillas, P.; Flannick, J.; Manning, A.; Grauman, P.V.; Mar, B.G.; Lindsley, R.C.; Mermel, C.H.; Burtt, N.; Chavez, A.; et al. Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. N. Engl. J. Med. 2014, 371, 2488–2498. [Google Scholar] [CrossRef] [PubMed]
- Wright, G.W.; Huang, D.W.; Phelan, J.D.; Coulibaly, Z.A.; Roulland, S.; Young, R.M.; Wang, J.Q.; Schmitz, R.; Morin, R.D.; Tang, J.; et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 2020, 37, 551–568.e514. [Google Scholar] [CrossRef] [PubMed]
- Kanda, Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013, 48, 452–458. [Google Scholar] [CrossRef]
- Scherer, F.; Kurtz, D.M.; Newman, A.M.; Stehr, H.; Craig, A.F.; Esfahani, M.S.; Lovejoy, A.F.; Chabon, J.J.; Klass, D.M.; Liu, C.L.; et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci. Transl. Med. 2016, 8, 364ra155. [Google Scholar] [CrossRef]
- Rossi, D.; Diop, F.; Spaccarotella, E.; Monti, S.; Zanni, M.; Rasi, S.; Deambrogi, C.; Spina, V.; Bruscaggin, A.; Favini, C.; et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood 2017, 129, 1947–1957. [Google Scholar] [CrossRef]
- Rivas-Delgado, A.; Nadeu, F.; Enjuanes, A.; Casanueva-Eliceiry, S.; Mozas, P.; Magnano, L.; Castrejón de Anta, N.; Rovira, J.; Dlouhy, I.; Martín, S.; et al. Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2021, 27, 513–521. [Google Scholar] [CrossRef]
- Spina, V.; Bruscaggin, A.; Cuccaro, A.; Martini, M.; Di Trani, M.; Forestieri, G.; Manzoni, M.; Condoluci, A.; Arribas, A.; Terzi-Di-Bergamo, L.; et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 2018, 131, 2413–2425. [Google Scholar] [CrossRef]
- Camus, V.; Viennot, M.; Lequesne, J.; Viailly, P.J.; Bohers, E.; Bessi, L.; Marcq, B.; Etancelin, P.; Dubois, S.; Picquenot, J.M.; et al. Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: A prospective study. Haematologica 2021, 106, 154–162. [Google Scholar] [CrossRef]
- Alig, S.; Macaulay, C.W.; Kurtz, D.M.; Dührsen, U.; Hüttmann, A.; Schmitz, C.; Jin, M.C.; Sworder, B.J.; Garofalo, A.; Shahrokh Esfahani, M.; et al. Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2021, 39, 2605–2616. [Google Scholar] [CrossRef]
- Meriranta, L.; Alkodsi, A.; Pasanen, A.; Lepistö, M.; Mapar, P.; Blaker, Y.N.; Jørgensen, J.; Karjalainen-Lindsberg, M.L.; Fiskvik, I.; Mikalsen, L.T.G.; et al. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood 2022, 139, 1863–1877. [Google Scholar] [CrossRef]
- Goldstein, J.; Kim, W.S.; Yoon, S.E.; Kim, S.J.; Roschewski, M.; Westin, J.; Lynch, R.C.; Alig, S.K.; Close, S.; Chabon, J.J.; et al. Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy. Blood 2023, 142, 187. [Google Scholar] [CrossRef]
- Mutter, J.A.; Alig, S.K.; Esfahani, M.S.; Lauer, E.M.; Mitschke, J.; Kurtz, D.M.; Kühn, J.; Bleul, S.; Olsen, M.; Liu, C.L.; et al. Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2023, 41, 1684–1694. [Google Scholar] [CrossRef]
- Kim, S.J.; Kim, J.J.; Park, M.R.; Park, B.; Ryu, K.J.; Yoon, S.E.; Kim, W.S.; Shin, S.; Lee, S.-T. Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma. Ann. Lab. Med. 2025, 45, 90–95. [Google Scholar] [CrossRef]
- Liang, J.-H.; Wu, Y.-F.; Shen, H.-R.; Li, Y.; Liang, J.-H.; Gao, R.; Hua, W.; Shang, C.-Y.; Du, K.-X.; Xing, T.-Y.; et al. Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma. Leukemia 2024, 38, 1541–1552. [Google Scholar] [CrossRef]
- Fu, H.; Wang, T.; Yang, Y.; Qiu, C.; Wang, H.; Qiu, Y.; Liu, J.; Liu, T. Next-generation sequencing of circulating tumor DNA in cerebrospinal fluid for detecting gene mutations in central nervous system lymphoma patients. Ther. Adv. Hematol. 2025, 16, 20406207251321721. [Google Scholar] [CrossRef]
- Nayyar, N.; White, M.D.; Gill, C.M.; Lastrapes, M.; Bertalan, M.; Kaplan, A.; D’Andrea, M.R.; Bihun, I.; Kaneb, A.; Dietrich, J.; et al. MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Adv. 2019, 3, 375–383. [Google Scholar] [CrossRef]
- Drandi, D.; Genuardi, E.; Dogliotti, I.; Ferrante, M.; Jiménez, C.; Guerrini, F.; Schirico, M.L.; Mantoan, B.; Muccio, V.; Lia, G.; et al. Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia. Haematologica 2018, 103, 1029–1037. [Google Scholar] [CrossRef]
- Camus, V.; Sarafan-Vasseur, N.; Bohers, E.; Dubois, S.; Mareschal, S.; Bertrand, P.; Viailly, P.J.; Ruminy, P.; Maingonnat, C.; Lemasle, E.; et al. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk. Lymphoma 2016, 57, 2171–2179. [Google Scholar] [CrossRef]
- Li, H. Toward better understanding of artifacts in variant calling from high-coverage samples. Bioinformatics 2014, 30, 2843–2851. [Google Scholar] [CrossRef]
- Rausch, T.; Zichner, T.; Schlattl, A.; Stütz, A.M.; Benes, V.; Korbel, J.O. DELLY: Structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 2012, 28, i333–i339. [Google Scholar] [CrossRef]
- Li, M.M.; Datto, M.; Duncavage, E.J.; Kulkarni, S.; Lindeman, N.I.; Roy, S.; Tsimberidou, A.M.; Vnencak-Jones, C.L.; Wolff, D.J.; Younes, A.; et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn. JMD 2017, 19, 4–23. [Google Scholar] [CrossRef] [PubMed]
- Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. Off. J. Am. Coll. Med. Genet. 2015, 17, 405–424. [Google Scholar] [CrossRef]
N = 52 | |
---|---|
Age, median (range) | 70 (28–84) |
Sex, n (%) | |
Male | 31 (59.6%) |
Female | 21 (40.4%) |
High LDH, n (%) | 44 (84.6%) |
Stage, n (%) | |
2 bulky | 4 (7.6%) |
3–4 | 48 (92.4%) |
PS ≥ 2, n (%) | 15 (28.8%) |
B-Symptom, n (%) | 20 (38.5%) |
IPI, n (%) | |
1–2 | 13 (25.0%) |
3 | 12 (23.1%) |
4–5 | 27 (51.9%) |
Final Response | Interim ctDNA ≥ 2-log Reduction (n = 37) | Interim ctDNA < 2-log Reduction (n = 15) | p-Value |
---|---|---|---|
CR (n = 37) | 28 (75.7%) | 9 (60.0%) | 0.724 |
PR (n = 2) | 2 (5.4%) | 0 (0.0%) | |
SD (n = 1) | 1 (2.7%) | 0 (0.0%) | |
PD (n = 11) | 6 (16.2%) | 5 (33.3%) | |
NA (n = 1) | 0 (0.0%) | 1 (6.6%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Song, G.-Y.; Park, J.H.; Kang, S.-R.; Han, S.J.; Jung, Y.; Son, M.; Jang, H.C.; Kim, M.; Ahn, S.-Y.; Jung, S.-H.; et al. Clinical Implication of Sequential Circulating Tumor DNA Assessments for the Treatment of Diffuse Large B-Cell Lymphoma. Cancers 2025, 17, 1734. https://doi.org/10.3390/cancers17111734
Song G-Y, Park JH, Kang S-R, Han SJ, Jung Y, Son M, Jang HC, Kim M, Ahn S-Y, Jung S-H, et al. Clinical Implication of Sequential Circulating Tumor DNA Assessments for the Treatment of Diffuse Large B-Cell Lymphoma. Cancers. 2025; 17(11):1734. https://doi.org/10.3390/cancers17111734
Chicago/Turabian StyleSong, Ga-Young, Joo Heon Park, Sae-Ryung Kang, Seung Jung Han, Youjin Jung, Minuk Son, Ho Cheol Jang, Mihee Kim, Seo-Yeon Ahn, Sung-Hoon Jung, and et al. 2025. "Clinical Implication of Sequential Circulating Tumor DNA Assessments for the Treatment of Diffuse Large B-Cell Lymphoma" Cancers 17, no. 11: 1734. https://doi.org/10.3390/cancers17111734
APA StyleSong, G.-Y., Park, J. H., Kang, S.-R., Han, S. J., Jung, Y., Son, M., Jang, H. C., Kim, M., Ahn, S.-Y., Jung, S.-H., Ahn, J.-S., Lee, J.-J., Kim, H.-J., & Yang, D.-H. (2025). Clinical Implication of Sequential Circulating Tumor DNA Assessments for the Treatment of Diffuse Large B-Cell Lymphoma. Cancers, 17(11), 1734. https://doi.org/10.3390/cancers17111734